X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35) 35
humans (29) 29
oncology (29) 29
chemotherapy (17) 17
hepatocellular carcinoma (14) 14
metastasis (12) 12
pancreatic cancer (11) 11
prognosis (11) 11
tumors (11) 11
animals (10) 10
cancer (10) 10
female (10) 10
male (10) 10
pancreatic ductal adenocarcinoma (10) 10
angiogenesis (9) 9
review (9) 9
aged (8) 8
antineoplastic agents - therapeutic use (8) 8
expression (8) 8
hematology (8) 8
middle aged (8) 8
survival (8) 8
carcinoma (7) 7
care and treatment (7) 7
treatment outcome (7) 7
analysis (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
cells (6) 6
gemcitabine (6) 6
hematology, oncology and palliative medicine (6) 6
medical prognosis (6) 6
sorafenib (6) 6
tumor microenvironment (6) 6
adult (5) 5
biomarkers (5) 5
cell biology (5) 5
development and progression (5) 5
health aspects (5) 5
immunotherapy (5) 5
liver cancer (5) 5
metastases (5) 5
molecular targeted therapy (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
patients (5) 5
recensioni (5) 5
retrospective studies (5) 5
adenocarcinoma (4) 4
bone metastases (4) 4
cancer therapies (4) 4
carcinoma, hepatocellular - drug therapy (4) 4
carcinoma, hepatocellular - pathology (4) 4
carcinoma, pancreatic ductal - pathology (4) 4
dendritic cells (4) 4
digestive system diseases (4) 4
ductal adenocarcinoma (4) 4
efficacy (4) 4
growth (4) 4
immunohistochemistry (4) 4
kaplan-meier estimate (4) 4
liver neoplasms - drug therapy (4) 4
liver neoplasms - pathology (4) 4
medicine, research & experimental (4) 4
mice (4) 4
micrornas - genetics (4) 4
multiple myeloma (4) 4
pancreatic neoplasms - diagnosis (4) 4
pancreatic neoplasms - drug therapy (4) 4
pancreatic neoplasms - pathology (4) 4
phase-ii trial (4) 4
predictive factor (4) 4
therapy (4) 4
vascular endothelial growth factor (4) 4
angiogenesis inhibitors - therapeutic use (3) 3
antigens (3) 3
antineoplastic agents - pharmacology (3) 3
apoptosis (3) 3
article (3) 3
bone neoplasms - secondary (3) 3
cancer research (3) 3
cancer-cells (3) 3
carcinoma, pancreatic ductal - genetics (3) 3
clinical trials as topic (3) 3
combination (3) 3
combined modality therapy (3) 3
disease-free survival (3) 3
double-blind (3) 3
endocrine system diseases (3) 3
endothelial growth-factor (3) 3
gene expression regulation, neoplastic (3) 3
hepatoma (3) 3
in-vitro (3) 3
inflammation (3) 3
insulin (3) 3
mast cells (3) 3
medicine & public health (3) 3
metformin (3) 3
monoclonal antibodies (3) 3
multidisciplinary sciences (3) 3
multivariate analysis (3) 3
neovascularization, pathologic - genetics (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BELFAGOR, ISSN 0005-8351, 11/1993, Volume 48, Issue 6, pp. 717 - 726
Journal Article
Cancers, ISSN 2072-6694, 11/2019, Volume 11, Issue 11, p. 1718
Background: Ablative techniques provide in patients with locally advanced pancreatic cancer (LAPC) symptomatic relief, survival benefit and potential... 
pancreatic cancer | locally advanced | pancreas | irreversible electroporation
Journal Article
Scientific Reports, ISSN 2045-2322, 02/2017, Volume 7, Issue 1, p. 42499
Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and... 
SURVIVAL | EFFICACY | MULTIDISCIPLINARY SCIENCES | CHEMOTHERAPY | Data processing | Hepatocellular carcinoma | Survival | Tumors
Journal Article
BMC Cancer, ISSN 1471-2407, 10/2015, Volume 15, Issue 1, p. 692
Journal Article
Clinical Case Reports, ISSN 2050-0904, 10/2019, Volume 7, Issue 10, pp. 1972 - 1976
PDAC bone metastases represent a clinical challenge characterized by multifaceted biological entity. PDAC bone metastases represent a clinical challenge... 
bone metastases | PDAC | zoledronic acid | pancreatic ductal adenocarcinoma | Antigens | Back pain | Spinal cord | Vertebra | T cell receptors | Metastasis | Family medical history | Radiation therapy | Patients | Cancer therapies | Chemotherapy | Fractures | Acids | Medical prognosis | Pancreatic cancer | Prostate
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 02/2017, Volume 18, Issue 2, pp. 418 - 418
Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory... 
Monoclonal antibodies | Angiogenesis | Vascular endothelial growth factor | Tyrosine kinase inhibitors | Biliary tract cancers | INTRAHEPATIC CHOLANGIOCARCINOMA | angiogenesis | BIOCHEMISTRY & MOLECULAR BIOLOGY | VEGF EXPRESSION | biliary tract cancers | PHASE-II | FACTOR-KAPPA-B | MICROVESSEL DENSITY | CHEMISTRY, MULTIDISCIPLINARY | tyrosine kinase inhibitors | LYMPH-NODE METASTASIS | vascular endothelial growth factor | TUMOR-ASSOCIATED MACROPHAGES | HUMAN GALLBLADDER CANCER | PROGNOSTIC-SIGNIFICANCE | monoclonal antibodies | ENDOTHELIAL GROWTH-FACTOR | Humans | Antineoplastic Agents - therapeutic use | Vascular Endothelial Growth Factor A - metabolism | Antineoplastic Agents - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Molecular Targeted Therapy | Vascular Endothelial Growth Factor A - genetics | Genetic Variation | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents - adverse effects | Biliary Tract Neoplasms - metabolism | Angiogenesis Inhibitors - therapeutic use | Biliary Tract Neoplasms - drug therapy | Gene Expression Regulation, Neoplastic - drug effects | Biliary Tract Neoplasms - genetics | Drug Evaluation, Preclinical | Angiogenesis Inhibitors - adverse effects | Biliary Tract Neoplasms - pathology | Treatment Outcome | Clinical Trials as Topic | Animals | Signal Transduction - drug effects | Models, Biological | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Neovascularization, Pathologic - genetics | Neovascularization, Pathologic - metabolism | Genes
Journal Article
Clinical and Experimental Medicine, ISSN 1591-8890, 8/2018, Volume 18, Issue 3, pp. 319 - 323
Mast cells are recognized as critical components of the tumor stromal microenvironment in several solid and hematological malignancies, promoting angiogenesis... 
Angiogenesis | Medicine & Public Health | Hematology | Pancreatic ductal adenocarcinoma | Internal Medicine | Oncology | Mast cells | PLUS GEMCITABINE | CANCER-CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | CARCINOMA CELLS | TRIAL | CARCINOGENESIS | INFLAMMATION | GENERATION | GROWTH-FACTOR | CROSSTALK | TUMOR MICROENVIRONMENT | Tryptases - metabolism | Interleukin-13 - antagonists & inhibitors | Humans | Pancreatic Neoplasms - blood supply | Gene Expression Regulation, Neoplastic | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Angiopoietin-1 - metabolism | Vascular Endothelial Growth Factor A - genetics | Platelet-Derived Growth Factor - genetics | Carcinoma, Pancreatic Ductal - genetics | Neovascularization, Pathologic - pathology | Pancreatic Neoplasms - drug therapy | Interleukin-13 - genetics | Tumor Microenvironment - genetics | Tryptases - antagonists & inhibitors | Mast Cells - metabolism | Angiogenesis Inhibitors - therapeutic use | Fibroblast Growth Factor 2 - metabolism | Neovascularization, Pathologic - prevention & control | Tryptases - genetics | Tumor Microenvironment - drug effects | Neoplasm Invasiveness | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - genetics | Interleukin-13 - metabolism | Carcinoma, Pancreatic Ductal - pathology | Mast Cells - drug effects | Angiopoietin-1 - antagonists & inhibitors | Disease Progression | Angiopoietin-1 - genetics | Carcinoma, Pancreatic Ductal - drug therapy | Cell Movement - drug effects | Fibroblast Growth Factor 2 - antagonists & inhibitors | Platelet-Derived Growth Factor - metabolism | Fibroblast Growth Factor 2 - genetics | Mast Cells - pathology | Neovascularization, Pathologic - genetics | Carcinoma, Pancreatic Ductal - blood supply | Platelet-Derived Growth Factor - antagonists & inhibitors | Adenocarcinoma | Medical colleges | Neurosciences | Analysis | Pancreatic cancer | Development and progression | Growth factors | Cells | Cell proliferation | Fibroblast growth factor 2 | Fibroblast growth factor | Platelet-derived growth factor | Leukocyte migration | Angiopoietin | Interleukin 13 | Metastases | Histamine | Pancreatic carcinoma | Tryptase | Degranulation | Vascular endothelial growth factor | Cell migration
Journal Article
CANCERS, ISSN 2072-6694, 04/2019, Volume 11, Issue 4, p. 539
Despite that the impact of immune checkpoint inhibitors on malignancies treatment is unprecedented, a lack of response to these molecules is observed in... 
GASTROINTESTINAL STROMAL TUMOR | angiogenesis | immune checkpoint inhibitors | COMBINATION | chemotherapy | tyrosine kinase inhibitors | BRAF INHIBITION | T-CELL INFILTRATION | MELANOMA | MICROENVIRONMENT | ONCOLOGY | IMMUNOTHERAPY | IMATINIB | INTESTINAL MICROBIOME | ANTI-PD-1
Journal Article
CANCERS, ISSN 2072-6694, 09/2019, Volume 11, Issue 9, p. 1270
Skeletal metastases of unknown primary (SMUP) represent a clinical challenge in dealing with patients diagnosed with bone metastases. Management of these... 
PROGNOSTIC-FACTORS | PRIMARY SITE | BIOCHEMICAL MARKERS | PHASE-II | PRIMARY ORIGIN | skeletal metastases of unknown primary | ZOLEDRONIC ACID | unknown primary tumor | SMUP | ONCOLOGY | bone metastases | BREAST-CANCER PATIENTS | DOUBLE-BLIND | bone markers | bisphosphonates | tumor microenvironment | LONG-TERM EFFICACY | BONE TURNOVER MARKERS
Journal Article
Journal Article
Medicina, ISSN 1010-660X, 10/2019, Volume 55, Issue 10, p. 698
Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70–80% of patients are... 
pembrolizumab | immune microenvironment | nivolumab | targeted therapies | hcc | immune checkpoint inhibitors | hepatocellular carcinoma
Journal Article
Medicina, ISSN 1010-660X, 10/2019, Volume 55, Issue 10, p. 707
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two... 
prognostic factors | sorafenib | hepatocellular carcinoma | predictive factors
Journal Article
CANCERS, ISSN 2072-6694, 06/2019, Volume 11, Issue 7, p. 942
Over the past several years there has been much debate with regards to the prognostic and clinical significance of pancreatic ductal adenocarcinoma (PDAC) with... 
CELLS | ACTIVATION | METASTASIS | ANGIOPOIETIN-LIKE 4 | CANCER | M2 macrophages | pancreatic cancer | PDAC | dendritic cells | ONCOLOGY | tumor immune microenvironment | PATHWAY | MST-1 | lymph node metastases | ANGPTL4 | WNT | PROGRESSION | XAV-939
Journal Article
European Journal of Cancer, ISSN 0959-8049, 04/2019, Volume 111, pp. 94 - 106
Journal Article
Cancers, ISSN 2072-6694, 03/2019, Volume 11, Issue 3, p. 330
Tumor-stroma interactions are of key importance for pancreatic ductal adenocarcinoma (PDAC) progression. Our aim was to investigate whether cancer associated... 
Nabpaclitaxel | Mast cells | CAFs | Gemcitabine | Pancreatic cancer | PATHWAYS | NAB-PACLITAXEL | RECEPTOR | INDUCTION | mast cells | MESENCHYMAL TRANSITION | FIBROBLASTS | CHEMOTHERAPY | pancreatic cancer | INHIBITION | ONCOLOGY | nabpaclitaxel | gemcitabine | EXPRESSION
Journal Article